Affordable Access

deepdyve-link
Publisher Website

Prospects for severe asthma treatment.

Authors
  • Calzetta, Luigino1
  • Matera, Maria Gabriella2
  • Coppola, Angelo3
  • Rogliani, Paola4
  • 1 Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy. Electronic address: [email protected] , (Italy)
  • 2 Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. , (Italy)
  • 3 Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy. , (Italy)
  • 4 Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. , (Italy)
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Dec 10, 2020
Volume
56
Pages
52–60
Identifiers
DOI: 10.1016/j.coph.2020.10.021
PMID: 33310456
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Biological drugs are approved to treat patients with severe uncontrolled asthma and are directed against mediators of type 2 immunity. These agents are effective in reducing the risk of exacerbation, maintaining asthma symptom control and reducing the need of systemic corticosteroids. Although biological drugs have revolutionized the management of the disease, to date there are no head-to-head studies across the current available molecules and there remains the need of specific biomarkers for the diagnosis, prognosis and response to treatment. Moreover, there is still an urgent need to identify further molecular targets to offer effective treatments for those patients who are not responsive to the currently available biological drugs, by moving upstream in the inflammatory cascade to inhibit multiple inflammatory pathways and/or identify effective nontype 2 immunity mechanisms. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times